Rejoni Names John Nealon as Chief Executive Officer to Lead Its Women’s Health MedTech Strategy
Rejoni Inc., a privately held clinical-stage biotechnology company focused on advancing uterine health through innovative biomaterial therapies, has announced the appointment of John Nealon as its new Chief Executive Officer. The leadership transition marks a pivotal moment for the company as it prepares to advance its lead product candidate, the Juveena® Hydrogel System, through regulatory review and toward potential commercialization.
Nealon brings more than two decades of experience in the medical device and women’s health sectors, with a career defined by operational leadership, product innovation, and successful commercialization strategies. His appointment reflects Rejoni’s strategic focus on strengthening its executive leadership as it moves closer to a critical inflection point in its development pipeline. With a proven track record of building and scaling healthcare companies, Nealon is expected to play a central role in guiding Rejoni through its next phase of growth.
Prior to joining Rejoni, Nealon served as Founder, President, and Chief Executive Officer of UroCure, a Minneapolis-based company specializing in minimally invasive solutions for female stress urinary incontinence. During his tenure, he successfully led the organization from early-stage development through regulatory approval with the U.S. Food and Drug Administration, established key strategic partnerships, and ultimately oversaw the company’s acquisition by LiNA Medical. This experience in navigating the full lifecycle of a medical device company—from concept to exit—positions him well to lead Rejoni as it seeks to bring its own innovation to market.
Earlier in his career, Nealon served as President and CEO of KSpine, where he led the development of a surgical treatment for scoliosis. He also held senior leadership roles at American Medical Systems, including Senior Vice President and General Manager of the Women’s Health Business. In that capacity, he managed one of the industry’s leading portfolios in gynecology and urology, gaining deep expertise in addressing complex conditions that affect women’s health. His academic background includes a Bachelor of Science in Chemical Engineering from Northwestern University and an MBA from the Kellogg School of Management, providing a strong foundation for both technical and business leadership.
The appointment comes as Rejoni continues to advance its flagship product, the Juveena Hydrogel System, which is currently under review by the FDA and remains an investigational device. The company was founded in 2020 by Amarpreet Sawhney, PhD, who will continue to serve as Chairman while also maintaining his role as Managing Director of Pramand LLC. Sawhney expressed strong confidence in Nealon’s ability to lead the company through this critical stage, highlighting his extensive experience in women’s health and his demonstrated success in bringing innovative medical technologies to market.
According to Sawhney, Nealon’s leadership arrives at a time when Rejoni is poised to make a meaningful impact in an area of significant unmet medical need. He emphasized that uterine health, particularly conditions such as intrauterine adhesions, has historically been underrecognized and underserved despite its profound implications for women’s reproductive health. With the Juveena Hydrogel System nearing regulatory evaluation, the company is entering a phase where commercial strategy, clinical execution, and stakeholder engagement will be essential to success.
Nealon, for his part, expressed enthusiasm about joining Rejoni and advancing its mission. He noted that uterine health represents a critical but often overlooked area within women’s healthcare, and he sees significant potential in Rejoni’s technology to address longstanding clinical challenges. He also highlighted the importance of collaboration with the company’s leadership team, investors, and clinical partners in bringing the Juveena Hydrogel System to patients and physicians.
At the core of Rejoni’s innovation is the Juveena® Hydrogel System, a proprietary transcervical implant designed to prevent the formation and recurrence of intrauterine adhesions (IUAs). These adhesions, which can develop following gynecological procedures such as hysteroscopic surgery, dilation and curettage (D&C), and fibroid removal, occur when scar tissue forms within the uterine cavity. IUAs can lead to a range of serious complications, including infertility, recurrent pregnancy loss, and abnormal menstrual bleeding.
Despite their significant impact, IUAs are often underdiagnosed, leaving many women without effective treatment options. Current approaches to managing IUAs are limited and may not adequately prevent recurrence, highlighting the need for innovative solutions. The Juveena Hydrogel System is designed to address this gap by acting as a physical barrier within the uterus, preventing opposing tissue surfaces from adhering during the healing process. By doing so, it aims to preserve the integrity of the uterine cavity and support better reproductive outcomes.
What sets Juveena apart is its biomaterial-based design, which enables it to be delivered transcervically without the need for invasive surgical implantation. This minimally invasive approach has the potential to improve patient comfort and reduce procedural complexity for physicians. Additionally, the hydrogel is engineered to provide temporary support during the critical healing period before being safely absorbed or cleared by the body.
The development of such a therapy aligns with broader trends in regenerative medicine and biomaterials, where innovative materials are being used to support tissue healing and prevent complications. By focusing on the underlying mechanisms of adhesion formation, Rejoni aims to move beyond symptomatic treatment and toward prevention, which could significantly improve patient outcomes.
As Rejoni advances toward potential FDA approval, the company faces both opportunities and challenges. Successfully navigating the regulatory process will be a key milestone, requiring robust clinical data, manufacturing readiness, and compliance with stringent safety and efficacy standards. At the same time, preparing for commercialization will involve building relationships with healthcare providers, educating clinicians about the benefits of the technology, and ensuring access for patients who may benefit from the therapy.
Nealon’s experience in these areas is expected to be instrumental. His background in launching and scaling medical device businesses, combined with his expertise in women’s health, positions him to guide Rejoni through the complexities of this transition. By leveraging his leadership, the company aims to accelerate the adoption of its technology and establish itself as a leader in uterine health innovation.
Looking ahead, Rejoni’s broader vision extends beyond a single product. The company is committed to developing a pipeline of biomaterial-based therapies that address a range of conditions affecting the uterus. By building on the platform established with Juveena, Rejoni seeks to create a new category of treatments that prioritize prevention, preservation, and healing.
In summary, the appointment of John Nealon as CEO represents a strategic step forward for Rejoni as it enters a critical phase of growth and development. With a strong leadership team, a promising investigational product, and a clear mission to address unmet needs in women’s health, the company is well positioned to make a meaningful impact in the field. As it continues to advance the Juveena Hydrogel System through regulatory review and toward potential commercialization, Rejoni’s progress will be closely watched by clinicians, investors, and patients alike, all of whom stand to benefit from innovations that improve uterine health and reproductive outcomes.
About Rejoni:
Rejoni, Inc. is a privately held company based in Bedford, MA, focused on developing and commercializing therapeutic products in gynecology using its proprietary biomaterials. Founded in 2020 by serial entrepreneur Amarpreet Sawhney, PhD and Pramand LLC, Rejoni is passionate about protecting, preserving, and healing the uterus. The company is dedicated to developing innovative solutions that preserve uterine health and empowering women through knowledge and education.
